IL300187A - Gene therapy CSRP3 (protein 3 rich in cysteine and glycine) - Google Patents
Gene therapy CSRP3 (protein 3 rich in cysteine and glycine)Info
- Publication number
- IL300187A IL300187A IL300187A IL30018723A IL300187A IL 300187 A IL300187 A IL 300187A IL 300187 A IL300187 A IL 300187A IL 30018723 A IL30018723 A IL 30018723A IL 300187 A IL300187 A IL 300187A
- Authority
- IL
- Israel
- Prior art keywords
- csrp3
- cysteine
- gene therapy
- rich protein
- glycine rich
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4716—Muscle proteins, e.g. myosin, actin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Immunology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061727P | 2020-08-05 | 2020-08-05 | |
| PCT/US2021/044412 WO2022031756A1 (en) | 2020-08-05 | 2021-08-03 | Csrp3 (cysteine and glycine rich protein 3) gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL300187A true IL300187A (en) | 2023-03-01 |
Family
ID=80118758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL300187A IL300187A (en) | 2020-08-05 | 2021-08-03 | Gene therapy CSRP3 (protein 3 rich in cysteine and glycine) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230257431A1 (https=) |
| EP (1) | EP4192962A4 (https=) |
| JP (1) | JP2023536618A (https=) |
| KR (1) | KR20230042468A (https=) |
| CN (1) | CN116234916A (https=) |
| AU (1) | AU2021321410A1 (https=) |
| BR (1) | BR112023001336A2 (https=) |
| CA (1) | CA3184983A1 (https=) |
| IL (1) | IL300187A (https=) |
| MX (1) | MX2023000994A (https=) |
| WO (1) | WO2022031756A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3021572A1 (en) | 2016-04-20 | 2017-10-26 | Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas | Compositions and methods for enhanced gene expression of pklr |
| EP3697452A4 (en) | 2017-10-16 | 2021-11-24 | Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, O.A., M.P. | LENTIVIRAL VECTORS FOR ADMINISTRATION OF PKLR TO TREAT PYRUVATE KINASE DEFECTS |
| BR112020020841A2 (pt) | 2018-04-11 | 2021-01-19 | Fundacion Para La Investigacion Biomedica Del Hospital Infantil Universitario Nino Jesus | Composições e métodos para transplante de célulastronco |
| CA3096293A1 (en) | 2018-04-27 | 2019-10-31 | Rocket Pharmaceuticals, Ltd. | Gene therapy for cns degeneration |
| MY209860A (en) | 2020-02-13 | 2025-08-07 | Tenaya Therapeutics Inc | Gene therapy vectors for treating heart disease |
| JP2023538519A (ja) | 2020-08-07 | 2023-09-08 | スペースクラフト セブン リミテッド ライアビリティ カンパニー | Aavベクターを使用したプラコフィリン-2(pkp2)遺伝子治療 |
| EP4479543A1 (en) * | 2022-02-18 | 2024-12-25 | Ginkgo Bioworks, Inc. | Gene therapy for arrhythmogenic cardiomyopathy |
| CA3255650A1 (en) * | 2022-03-18 | 2023-09-21 | Aavantibio, Inc. | METHODS AND COMPOSITIONS FOR TREATING RBM20-RELATED CARDIOMYOPATHY WITH A VIRAL VECTOR |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10004857A1 (de) * | 2000-02-03 | 2001-08-16 | Schering Ag | MLP-Gen, Nukleinsäuren, Polypeptide und deren Verwendung |
| WO2009012176A2 (en) | 2007-07-14 | 2009-01-22 | The University Of Iowa Research Foundation | Methods and compositions for treating brain diseases |
| EP2792742A1 (en) * | 2013-04-17 | 2014-10-22 | Universitätsklinikum Hamburg-Eppendorf (UKE) | Gene-therapy vectors for treating cardiomyopathy |
| US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
| IL248102B (en) | 2014-05-02 | 2022-07-01 | Genzyme Corp | aav vectors for gene therapy of the central nervous system and retina |
| KR102423442B1 (ko) | 2015-12-11 | 2022-07-20 | 캘리포니아 인스티튜트 오브 테크놀로지 | 아데노-관련 바이러스를 지시하기 위한 타겟팅 펩타이드 |
| MX2019011046A (es) * | 2017-03-17 | 2019-10-17 | Res Inst Nationwide Childrens Hospital | Administracion de vectores del virus adenoasociado de microdistrofina especifica del musculo para tratar la distrofia muscular. |
| SG11202002276VA (en) * | 2017-09-20 | 2020-04-29 | 4D Molecular Therapeutics Inc | Adeno-associated virus variant capsids and methods of use thereof |
| AU2019258830B2 (en) * | 2018-04-27 | 2025-12-18 | Universität Heidelberg | Modified AAV capsid polypeptides for treatment of muscular diseases |
| US20210260215A1 (en) * | 2018-06-08 | 2021-08-26 | University Of Florida Research Foundation, Incorporated | Aav cardiac gene therapy for cardiomyopathy |
| CN114450411A (zh) * | 2019-04-01 | 2022-05-06 | 特纳亚治疗股份有限公司 | 具有工程化衣壳的腺相关病毒 |
-
2021
- 2021-08-03 BR BR112023001336A patent/BR112023001336A2/pt unknown
- 2021-08-03 IL IL300187A patent/IL300187A/en unknown
- 2021-08-03 JP JP2023507388A patent/JP2023536618A/ja active Pending
- 2021-08-03 CA CA3184983A patent/CA3184983A1/en active Pending
- 2021-08-03 KR KR1020237003436A patent/KR20230042468A/ko active Pending
- 2021-08-03 AU AU2021321410A patent/AU2021321410A1/en active Pending
- 2021-08-03 EP EP21852527.7A patent/EP4192962A4/en active Pending
- 2021-08-03 US US18/019,396 patent/US20230257431A1/en active Pending
- 2021-08-03 WO PCT/US2021/044412 patent/WO2022031756A1/en not_active Ceased
- 2021-08-03 MX MX2023000994A patent/MX2023000994A/es unknown
- 2021-08-03 CN CN202180057650.8A patent/CN116234916A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230257431A1 (en) | 2023-08-17 |
| JP2023536618A (ja) | 2023-08-28 |
| CN116234916A (zh) | 2023-06-06 |
| MX2023000994A (es) | 2023-03-01 |
| EP4192962A1 (en) | 2023-06-14 |
| KR20230042468A (ko) | 2023-03-28 |
| WO2022031756A1 (en) | 2022-02-10 |
| EP4192962A4 (en) | 2025-04-23 |
| BR112023001336A2 (pt) | 2023-02-14 |
| CA3184983A1 (en) | 2022-02-10 |
| AU2021321410A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL300187A (en) | Gene therapy CSRP3 (protein 3 rich in cysteine and glycine) | |
| SG11202106771QA (en) | Single-molecule protein and peptide sequencing | |
| PH12021550789A1 (en) | Disulfide bond stabilized polypeptide compositions and methods of use | |
| EP1751179A4 (en) | PEPTIDES DERIVED FROM THE CASEIN AND THEIR THERAPEUTIC USES | |
| IL305809A (en) | Cancer neoantigenic peptides and their use | |
| MX2021008207A (es) | Proteínas de fusión multifuncionales y usos de las mismas. | |
| GB0202633D0 (en) | Stabilization of protein preparations | |
| EP3946410A4 (en) | Therapeutic interferon alpha 1 proteins | |
| IL308790A (en) | Clamped peptides and their methods | |
| IL299907A (en) | Paired peptides and their methods | |
| MXPA05008704A (es) | Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas. | |
| IL292047A (en) | Proteins containing various, multiple unnatural amino acids and methods for preparing and using such proteins | |
| GB202006974D0 (en) | Chimaeric proteins and therapeutic agents | |
| IL319851A (en) | LRRC-15 binding protein structures and uses thereof | |
| EP4279507A4 (en) | CD73-BINDING PROTEIN AND USE THEREOF | |
| GB0216972D0 (en) | Peptides and peptide derivaties for the treatment of &-synuclein-related diseases | |
| ZA202108909B (en) | Formulation for oral delivery of proteins, peptides and small molecules with poor permeability | |
| IL316176A (en) | SIGLEC-8 binding proteins and their uses | |
| HK40094212A (en) | Csrp3 (cysteine and glycine rich protein 3) gene therapy | |
| EP4269428A4 (en) | NEW PEPTIDE AND ITS USE | |
| EP4163288A4 (en) | NEW NUCLEOLIN-BINDING PEPTIDE AND USE THEREOF | |
| EP4146671A4 (en) | NEW PROTEIN AND THERAPEUTIC AND COSMETIC USES THEREOF | |
| EP4446335A4 (en) | NEW PEPTIDE AND ITS USE | |
| IL311185A (en) | MOG-binding proteins and uses thereof | |
| GB202403250D0 (en) | Fgf21 mutant protein and use thereof |